Ami Fadia
Stock Analyst at Needham
(4.97)
# 88
Out of 4,630 analysts
626
Total ratings
59.4%
Success rate
36.1%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Reiterated: Buy | $50 | $46.14 | +8.37% | 10 | Aug 7, 2026 | |
| RVMD Revolution Medicines | Rated: Buy | $235 → $240 | $205.15 | +16.99% | 34 | Aug 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $575 → $582 | $360.76 | +61.33% | 26 | Aug 6, 2026 | |
| GHRS GH Research | Maintained: Buy | $32 → $39 | $30.27 | +28.84% | 6 | Aug 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $38 | $29.21 | +30.09% | 38 | Aug 5, 2026 | |
| IMRX Immuneering | Reiterated: Buy | $11 → $18 | $4.51 | +299.11% | 32 | Aug 5, 2026 | |
| JAZZ Jazz Pharmaceuticals | Rated: Buy | $255 → $292 | $256.56 | +13.81% | 70 | Aug 4, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintained: Buy | $45 → $50 | $38.41 | +30.17% | 53 | Aug 4, 2026 | |
| NBIX Neurocrine Biosciences | Rated: Buy | $200 → $204 | $163.41 | +24.84% | 44 | Jul 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Buy | $15 → $14 | $4.17 | +235.73% | 44 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $49.17 | +26.09% | 18 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $256 | $207.94 | +23.11% | 70 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.63 | +206.75% | 20 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $12.17 | +269.76% | 8 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.25 | - | 10 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $255 | $212.74 | +19.86% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $42.39 | - | 27 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €108.00 | €78.40 | n/a | 8 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $11.91 | n/a | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $7.93 | n/a | 2 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $15 | $4.00 | n/a | 3 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.43 | n/a | 6 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $63 | $12.84 | n/a | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5.5 → $6 | $18.14 | n/a | 9 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 | $14.36 | n/a | 9 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $75 | $25.02 | n/a | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.000001 | n/a | 5 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $7 | $0.000001 | n/a | 3 | Dec 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $24 | $0.4908 | n/a | 9 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 → $1.5 | $0.00001 | n/a | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $9 | $18.51 | n/a | 4 | Aug 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $12 → $14 | $35.36 | n/a | 11 | Aug 6, 2020 |
Definium Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $50
Current: $46.14
Upside: +8.37%
Revolution Medicines
Aug 6, 2026
Rated: Buy
Price Target: $235 → $240
Current: $205.15
Upside: +16.99%
Praxis Precision Medicines
Aug 6, 2026
Maintained: Buy
Price Target: $575 → $582
Current: $360.76
Upside: +61.33%
GH Research
Aug 6, 2026
Maintained: Buy
Price Target: $32 → $39
Current: $30.27
Upside: +28.84%
ACADIA Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $38
Current: $29.21
Upside: +30.09%
Immuneering
Aug 5, 2026
Reiterated: Buy
Price Target: $11 → $18
Current: $4.51
Upside: +299.11%
Jazz Pharmaceuticals
Aug 4, 2026
Rated: Buy
Price Target: $255 → $292
Current: $256.56
Upside: +13.81%
Harmony Biosciences Holdings
Aug 4, 2026
Maintained: Buy
Price Target: $45 → $50
Current: $38.41
Upside: +30.17%
Neurocrine Biosciences
Jul 31, 2026
Rated: Buy
Price Target: $200 → $204
Current: $163.41
Upside: +24.84%
Bicycle Therapeutics
Jul 30, 2026
Maintained: Buy
Price Target: $15 → $14
Current: $4.17
Upside: +235.73%
Jul 29, 2026
Reiterated: Buy
Price Target: $62
Current: $49.17
Upside: +26.09%
Jul 29, 2026
Maintained: Buy
Price Target: $256
Current: $207.94
Upside: +23.11%
Jul 27, 2026
Maintained: Buy
Price Target: $5
Current: $1.63
Upside: +206.75%
Jul 27, 2026
Maintained: Buy
Price Target: $45
Current: $12.17
Upside: +269.76%
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.25
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $225 → $255
Current: $212.74
Upside: +19.86%
May 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $42.39
Upside: -
Apr 25, 2025
Reiterated: Buy
Price Target: €108.00
Current: €78.40
Upside: n/a
Dec 14, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $11.91
Upside: n/a
Mar 10, 2021
Reiterated: Buy
Price Target: $10 → $7
Current: $7.93
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $10 → $15
Current: $4.00
Upside: n/a
Mar 2, 2021
Rated: Hold
Price Target: n/a
Current: $16.43
Upside: n/a
Mar 1, 2021
Rated: Buy
Price Target: $63
Current: $12.84
Upside: n/a
Feb 26, 2021
Rated: Hold
Price Target: $5.5 → $6
Current: $18.14
Upside: n/a
Feb 25, 2021
Rated: Buy
Price Target: $16
Current: $14.36
Upside: n/a
Feb 25, 2021
Rated: Hold
Price Target: $75
Current: $25.02
Upside: n/a
Jan 11, 2021
Reiterated: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Dec 30, 2020
Maintained: Buy
Price Target: $10 → $7
Current: $0.000001
Upside: n/a
Dec 2, 2020
Maintained: Buy
Price Target: $19 → $24
Current: $0.4908
Upside: n/a
Oct 1, 2020
Maintained: Hold
Price Target: $1 → $1.5
Current: $0.00001
Upside: n/a
Aug 14, 2020
Maintained: Buy
Price Target: $8 → $9
Current: $18.51
Upside: n/a
Aug 6, 2020
Maintained: Hold
Price Target: $12 → $14
Current: $35.36
Upside: n/a